Advances in the Treatment of Renal Cell Carcinoma

doi:10.3390/books978-3-0365-2934-9

Format

Hardback

License and Copyright

Keywords

renal cell carcinoma; autophagy; hydroxychloroquine; chloroquine; ROC-325; cysteine cathepsins; cysteine cathepsin inhibitors; lysosome; renal cancer; metastatic renal cell carcinoma; immune-based combination therapies; network meta-analysis; renal cell carcinoma; PD-L1; predictive; biomarker; treatment; TKIs; mRCC; biomarkers; soluble factors; biomarkers; immunotherapy; renal cell carcinoma; PD-L1; renal cell carcinoma (RCC); sunitib resistance; artesunate (ART); Traditional Chinese Medicine (TCM); growth inhibition; ferroptosis; reactive oxygen species (ROS); clear cell renal cell carcinoma; ccRCC; RCC; kidney cancer; evolution; evolutionary trajectory; biomarker; metastatic; renal cell carcinoma; second line therapy; renal cell cancer; immune checkpoint inhibitors; tyrosine kinase inhibitors; biomarkers; individualization; clear cell renal cell carcinoma; immune checkpoint inhibitors; biomarker; genomic signature; transcriptomic analysis

Reprint

Download Flyer

Advances in the Treatment of Renal Cell Carcinoma

Edited by

February 2022

221 pages

ISBN978-3-0365-2935-6 (Hardback)
ISBN978-3-0365-2934-9 (PDF)

https://doi.org/10.3390/books978-3-0365-2934-9

Free Download (PDF)

This is a Reprint of the Special Issue Advances in the Treatment of Renal Cell Carcinoma that was published in

Biology & Life Sciences

Medicine & Pharmacology

Summary

This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon.